The Department of Health (Department), Division of HIV Health, located at 625 Forster Street Harrisburg, PA 17120 is soliciting a U.S. Food and Drug Administration (FDA) approved Clinical Laboratory Improvement Amendments (CLIA) waived rapid dual platform HIV/syphilis combination test, and an FDA approved CLIA waived rapid hepatitis C test, or an FDA approved CLIA waived combination of rapid tests for HIV, syphilis and hepatitis C. This contract will be effective for one year, with an option for two, two-year renewals. Technical Requirements Technical requirements for services include the following: The contractor shall maintain an inventory of test kits, controls, and Micro Readers, if required for the testing technology, that will ship directly to a network of providers as they are requested. The contractor shall provide no cost virtual training on the testing technology, technical assistance, and troubleshooting to providers on the use of the testing technology during hours mutually established by the Department and Contractor, for one-year after each purchase. FDA approved CLIA waived dual platform HIV/Syphilis combination test(s) must include: Controls specific to the HIV/Syphilis combination test; Micro Readers for HIV/Syphilis combination test. FDA approved CLIA waived rapid hepatitis C test must include: Controls specific to the hepatitis C test; Micro Readers for the hepatitis C test. FDA approved CLIA waived combination of rapid HIV, syphilis and hepatitis C tests must include: Controls specific to the combination of tests; Micro Readers for the combination of tests.
